» Articles » PMID: 38731604

(Fr.) Singer β-1,3-Glucanoligosaccharide (Ps-GOS) Suppresses RANKL-Induced Osteoclast Differentiation and Function in Pre-Osteoclastic RAW 264.7 Cells by Inhibiting the RANK/NFκB/cFOS/NFATc1 Signalling Pathway

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2024 May 11
PMID 38731604
Authors
Affiliations
Soon will be listed here.
Abstract

Edible grey oyster mushroom, , β (1,3), (1,6) glucan possesses a wide range of biological activities, including anti-inflammation, anti-microorganism and antioxidant. However, its biological activity is limited by low water solubility resulting from its high molecular weight. Our previous study demonstrated that enzymatic hydrolysis of grey oyster mushroom β-glucan using β-1,3-glucanase isozymes obtains a lower molecular weight and higher water solubility, glucanoligosaccharide (Ps-GOS). Additionally, Ps-GOS potentially reduces osteoporosis by enhancing osteoblast-bone formation, whereas its effect on osteoclast-bone resorption remains unknown. Therefore, our study investigated the modulatory activities and underlying mechanism of Ps-GOS on Receptor activator of nuclear factor kappa-Β ligand (RANKL) -induced osteoclastogenesis in pre-osteoclastic RAW 264.7 cells. Cell cytotoxicity of Ps-GOS on RAW 264.7 cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and its effect on osteoclast differentiation was determined by tartrate-resistant acid phosphatase (TRAP) staining. Additionally, its effect on osteoclast bone-resorptive ability was detected by pit formation assay. The osteoclastogenic-related factors were assessed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), Western blot and immunofluorescence. The results revealed that Ps-GOS was non-toxic and significantly suppressed the formation of mature osteoclast multinucleated cells and their resorption activity by reducing the number of TRAP-positive cells and pit formation areas in a dose-dependent manner. Additionally, Ps-GOS attenuated the nuclear factor kappa light chain-enhancer of activated B cells' P65 (NFκB-P65) expression and their subsequent master osteoclast modulators, including nuclear factor of activated T cell c1 (NFATc1) and Fos proto-oncogene (cFOS) via the NF-κB pathway. Furthermore, Ps-GOS markedly inhibited RANK expression, which serves as an initial transmitter of many osteoclastogenesis-related cascades and inhibited proteolytic enzymes, including TRAP, matrix metallopeptidase 9 (MMP-9) and cathepsin K (CTK). These findings indicate that Ps-GOS could potentially be beneficial as an effective natural agent for bone metabolic disease.

Citing Articles

Exploring the Potential of in Managing Bone Loss: Insights from Preclinical Studies.

Hairi H, Jusoh R, Sadikan M, Hasan W, Shuid A Int J Med Sci. 2025; 22(4):819-833.

PMID: 39991771 PMC: 11843146. DOI: 10.7150/ijms.103241.

References
1.
Jung M, Kim J, Kim K, Choi S, Ku S . Polycan, a β-glucan from SM-2001, mitigates ovariectomy-induced osteoporosis in rats. Exp Ther Med. 2016; 12(3):1251-1262. PMC: 4998138. DOI: 10.3892/etm.2016.3485. View

2.
Garber K . Two pioneering osteoporosis drugs finally approach approval. Nat Rev Drug Discov. 2016; 15(7):445-6. DOI: 10.1038/nrd.2016.132. View

3.
Hara S, Nagai-Yoshioka Y, Yamasaki R, Adachi Y, Fujita Y, Watanabe K . Dectin-1-mediated suppression of RANKL-induced osteoclastogenesis by glucan from baker's yeast. J Cell Physiol. 2020; 236(7):5098-5107. DOI: 10.1002/jcp.30217. View

4.
Kim H, Cho H, Moon S, Shin H, Yang K, Park B . Effects of beta-glucan from Aureobasidium pullulans on acute inflammation in mice. Arch Pharm Res. 2007; 30(3):323-8. DOI: 10.1007/BF02977613. View

5.
Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A . Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. Physiol Rev. 2017; 97(4):1295-1349. DOI: 10.1152/physrev.00036.2016. View